Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 2/20 | 0.52 |
| ▸ | OTC | P00480 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | ARG2 | P78540 | 4/20 | 0.39 |
| ▸ | ARG1 | P05089 | 3/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30033086 | 1.00 | DDAH1 (0.52) | DDAH1OTCGSRDPP7DPP8 | |
| SCHEMBL9966613 | 1.00 | DDAH1 (0.52) | DDAH1OTCGSRDPP7DPP8 | |
| Hydrochloric Acid SCHEMBL30096368 | 0.99 | DDAH1 (0.51) | DDAH1OTCGSRDPP7DPP8 | |
| SCHEMBL7194971 | 0.95 | DDAH1 (0.57) | DDAH1OTCGSRDPP7DPP8 | |
| SCHEMBL22281180 | 0.95 | DDAH1 (0.57) | DDAH1OTCGSRDPP7DPP8 | |
| SCHEMBL28297586 | 0.95 | DDAH1 (0.57) | DDAH1OTCGSRDPP7DPP8 | |
| SCHEMBL24185361 | 0.89 | DDAH1 (0.46) | DDAH1OTCGSRSLC1A3SLC1A1 | |
| SCHEMBL31710914 | 0.89 | DDAH1 (0.53) | DDAH1OTCGSRDPP7DPP8 | |
| SCHEMBL30310821 | 0.88 | DDAH1 (0.43) | DDAH1DPP7DPP8ANPEPDPP4 | |
| SCHEMBL24946771 | 0.88 | DDAH1 (0.44) | DDAH1OTCGSRDPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 349 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | claimed |
| US-20240158735-A1 | METHODS AND COMPOSITIONS USING AN ENGINEERED RELEASE FACTOR | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-05-16 | — | — | US | claimed |
| CN-116601297-A | Modified helicase and application thereof | 北京齐碳科技有限公司 | 2023-08-15 | — | — | CN | claimed |
| US-20230212535-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-07-06 | — | — | US | claimed |
| EP-4198125-A2 | PIF1-LIKE HELICASE AND USE THEREOF | Qitan Technology Ltd., Beijing (CN) | 2023-06-21 | — | — | EP | claimed |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. | 2022-12-22 | — | — | US | claimed |
| US-11525125-B2 | Modified helicases | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2022-12-13 | — | — | US | claimed |
| EP-4063382-A9 | PIF1-LIKE HELICASE AND APPLICATION THEREOF | Qitan Technology Ltd., Beijing (CN) | 2022-11-16 | — | — | EP | claimed |
| EP-4063382-A1 | PIF1-LIKE HELICASE AND APPLICATION THEREOF | Qitan Technology Ltd., Beijing (CN) | 2022-09-28 | — | — | EP | claimed |
| US-20220290223-A1 | PIF1-LIKE HELICASE AND USE THEREOF | Qitan Technology Ltd. (CN) | 2022-09-15 | — | — | US | claimed |
| CN-114599666-A | Pif1-like helicase and application thereof | 北京齐碳科技有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-113930406-A | Pif1-like helicase and application thereof | 北京齐碳科技有限公司 | 2022-01-14 | — | — | CN | claimed |
| CN-105899678-A | Modified enzymes | 牛津纳米孔技术公司 | 2016-08-24 | — | — | CN | claimed |
| US-6590061-B1 | Synthetic polypeptide or peptides having narrow molecular weight distribution used as telechelic polymers for synthesis of block or graft copolymers | INSTITUTE OF MACROMOLECULAR CHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2003-07-08 | — | — | US | claimed |
| EP-1088020-B1 | FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | USTAV MAKROMOLEKULARNI CHEMIE (CZ) | 2002-12-18 | — | — | EP | claimed |
| EP-1088020-A1 | FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | USTAV MAKROMOLEKULARNI CHEMIE AKADEMIE VED CESKE REPUBLIKY (CZ) | 2001-04-04 | — | — | EP | claimed |
| WO-1999064495-A1 | FUNCTIONALISED POLYMERS OF α-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | ÚSTAV MAKROMOLEKULÁRNÍ CHEMIE AKADEMIE VĚD ČESKÉ REPUBLIKY (CZ) | 1999-12-16 | — | — | WO | claimed |
| CN-122036912-A | Cytokine conjugates for the treatment of proliferative and infectious diseases | 辛索克斯公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-1088020-A1 | FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | USTAV MAKROMOLEKULARNI CHEMIE AKADEMIE VED CESKE REPUBLIKY (CZ) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999064495-A1 | FUNCTIONALISED POLYMERS OF α-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | ÚSTAV MAKROMOLEKULÁRNÍ CHEMIE AKADEMIE VĚD ČESKÉ REPUBLIKY (CZ) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | DDAH1 3874/4885OTC 4590/4885GSR 3905/4885 |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | DDAH1 3874/4885OTC 4590/4885GSR 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.